CenterBook Partners LP Trims Stock Holdings in Natera, Inc. $NTRA

CenterBook Partners LP trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 76.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,053 shares of the medical research company’s stock after selling 25,642 shares during the period. CenterBook Partners LP’s holdings in Natera were worth $1,845,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of NTRA. Palladiem LLC bought a new stake in shares of Natera during the fourth quarter valued at about $31,000. Horizon Investments LLC bought a new stake in shares of Natera during the third quarter valued at about $32,000. Flagship Harbor Advisors LLC bought a new stake in shares of Natera during the fourth quarter valued at about $41,000. Sound Income Strategies LLC increased its position in shares of Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the period. Finally, TD Waterhouse Canada Inc. bought a new stake in shares of Natera during the fourth quarter valued at about $62,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the sale, the insider owned 137,643 shares in the company, valued at approximately $30,065,360.49. This trade represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 159,500 shares of company stock valued at $34,664,208 in the last ninety days. 5.05% of the stock is owned by insiders.

Natera Stock Performance

Shares of NTRA stock opened at $222.82 on Wednesday. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36. The company has a market capitalization of $31.91 billion, a PE ratio of -136.70 and a beta of 1.56. The business’s fifty day moving average is $205.34 and its 200 day moving average is $216.16.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler reissued an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Wells Fargo & Company boosted their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.